Cost-effectiveness analysis of routine 13-valent pneumococcal conjugate vaccinations in Chinese infants

Zhou, Hua; He, Jinchun; Wu, Bin; Che, Dongsheng

doi:10.1080/21645515.2018.1438794

Cited by 14 publications

(26 citation statements)

References 36 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Seven studies assessed the cost-effectiveness of PCV-7 [27,29,30,32,33,39,46], of which one study assessed its effectiveness in the context of typical and pandemic influenza seasons [30]. PCV-13 was assessed in six studies [35,38,40,41,43,45] and comparisons of various types of vaccines were performed in two studies [26,48]. The majority of studies used quality-adjusted life years (QALYs) or disability-adjusted life years (DALYs) as the health outcomes measure [20,25,26,32,[35][36][37][38][39][40][41]44,47,48] while the rest combined both the clinical and the utility outcomes or provided only clinical outcomes, e.g., cases of pneumococcal-related diseases and life years.…”

Section: Methodsmentioning

confidence: 99%

“…PCV-13 was assessed in six studies [35,38,40,41,43,45] and comparisons of various types of vaccines were performed in two studies [26,48]. The majority of studies used quality-adjusted life years (QALYs) or disability-adjusted life years (DALYs) as the health outcomes measure [20,25,26,32,[35][36][37][38][39][40][41]44,47,48] while the rest combined both the clinical and the utility outcomes or provided only clinical outcomes, e.g., cases of pneumococcal-related diseases and life years. Three studies performed both a CUA and a budget impact analysis (BIA) [31,37,45], while one study performed CEA and BIA [39].…”

Section: Methodsmentioning

confidence: 99%

“…Within the included studies, a 3% discount rate was adopted in the majority of the studies (n = 16) [20,26,27,32,33,[37][38][39][40][41][42][43][44]47,48]. One study used a 3.5% discount rate [31], while another seven studies used a 5% discount rate [25,28,29,[34][35][36]46]. One study reported the discount rate only for the cost, not for the effects (5%) [30].…”

Section: Methodsmentioning

confidence: 99%

“…The included studies were conducted in 11 Asian countries, including China (n = 7) [26,30,32,33,35,41,48] Malaysia (n = 3) [34,42,44], Hong Kong (n = 3) [28,29,42] Korea (n = 2) [25,46], The Philippines (n = 2) [31,36],Taiwan (n = 2) [27,43], Japan (n = 3) [20,38,39], Thailand (n = 1) [47], Mongolia (n = 1) [45], Bhutan (n = 1) [37], and India (n = 1) [40] (Table 1). One study was a multiple country analysis, performed in Malaysia and Hong Kong [42].…”

Section: Characteristics Of Included Studiesmentioning

confidence: 99%

See 3 more Smart Citations

Pneumococcal Vaccination for Children in Asian Countries: A Systematic Review of Economic Evaluation Studies

et al. 2020

View full text Add to dashboard Cite

Background: Evidence on costs and health benefits of pneumococcal conjugate vaccine (PCV) for children in Asian countries is limited but growing. As a region with a considerably high burden of pneumococcal disease, it is prominent to have a comprehensive overview on the cost-effectiveness of implementing and adopting a PCV vaccination program. Methods: We conducted a systematic review from Pubmed and Embase to identify economic evaluation studies of PCV for children in Asian countries up to May 2020. Data extraction included specific characteristics of the study, input parameters, cost elements, cost-effectiveness results, and key drivers of uncertainty. The Preferred Reporting Items for Systematic Reviews and Meta Analyses (PRISMA) statement was followed for this systematic review. The reporting quality of the included studies was evaluated using the Consolidated Health Economic Evaluation Reporting Standards (CHEERS) statement. Results: After the screening process on both the title and abstract and full text of 518 records, a total of 25 studies fulfilled the inclusion criteria, and were included in the review. The majority of included studies demonstrates that PCV for children is cost-effective in most of the Asian region, and even cost-saving in some countries. Most of the included studies implemented cost utility analysis (CUA) using either quality-adjusted life years (QALYs) or disability-adjusted life years (DALYs). Overall, the main drivers affecting the cost effectiveness were vaccine price, burden regarding pneumonia-related parameters, and the inclusion of herd effects. Conclusion: The children pneumococcal vaccination program appears to be a cost-effective intervention in Asia, and even cost-saving in certain conditions. Vaccine price, pneumonia-related disease burden, and the inclusion of the herd effect are observed as important key drivers in estimating cost-effectiveness in this region. Incorporating PCV in vaccination programs in this region was found to be highly favorable.

show abstract

Section: Methodsmentioning

confidence: 99%

Section: Methodsmentioning

confidence: 99%

Section: Methodsmentioning

confidence: 99%

Section: Characteristics Of Included Studiesmentioning

confidence: 99%

See 2 more Smart Citations

Pneumococcal Vaccination for Children in Asian Countries: A Systematic Review of Economic Evaluation Studies

et al. 2020

View full text Add to dashboard Cite

show abstract

“…1,2 Pneumococcal disease is preventable, and the widespread use of pneumococcal polysaccharide-based vaccines has remarkably reduced the incidence of this disease associated with vaccine-covered serotypes, especially conjugate pneumococcal vaccine which could induce T cell response and longer immunity has successfully reduced pediatric pneumococcal disease incidence. [3][4][5][6][7] However, the limited serotype coverage of this type of vaccine currently cannot completely protect people against all of the more than 90 serotypes of S. pneumoniae, and the replacement of non-vaccine coverage serotypes in pneumococcal infections is of great concern with the use of polysaccharide-based vaccines. [8][9][10] Therefore, developing an alternative vaccine with broad coverage against pneumococcal diseases would be beneficial.…”

Section: Introductionmentioning

confidence: 99%

Broad protective immune responses elicited by bacterium-like particle-based intranasal pneumococcal particle vaccine displaying PspA2 and PspA4 fragments

Guo

Wang

et al. 2018

Human Vaccines & Immunotherapeutics

View full text Add to dashboard Cite

Streptococcus pneumoniae is an infectious pathogen mainly infecting host bodies through the respiratory system. An effective pneumococcal vaccine would be targeted to the mucosa and provide not only protection against invasive infection but also against colonization in the respiratory system. In the present work, we applied bacterium-like particles (BLPs) as an adjuvant for the development of a PspA mucosal vaccine, in which the PspA protein was displayed on the surface of BLPs. Intranasal immunization with the PspA-BLP pneumococcal vaccine, comprised of PspA2 from pneumococcal family 1 and PspA4 from pneumococcal family 2, not only induced a high level of serum IgG antibodies but also a high level of mucosal SIgA antibodies. Analysis of binding of serum antibodies to intact bacteria showed a broad coverage of binding to pneumococcal strains expressing PspA from clade 1 to 5. Immunization with the PspA-BLP vaccine conferred protection against fatal intranasal challenge with both PspA family 1 and family 2 pneumococcal strains regardless of serotype. Therefore, the PspA-BLP pneumococcal vaccine was demonstrated to be a promising strategy for mucosal immunization to enhance both systemic and mucosal immune responses.

show abstract

Herd Immunity Effects in Cost-Effectiveness Analyses among Low- and Middle-Income Countries

Lavelle

Ollendorf

et al. 2022

Appl Health Econ Health Policy

View full text Add to dashboard Cite

Background Herd immunity (HI) is a key benefit of vaccination programs, but the effects are not routinely included in cost-effectiveness analyses (CEAs). Objective This study investigated how the inclusion of HI in CEAs may influence the reported value of immunizations in low- and middle-income countries (LMICs) and illustrated the implications for COVID-19 immunization. Methods We reviewed immunization CEAs published from 2000 to 2018 focusing on LMICs using data from the Tufts Medical Center CEA Registries. We investigated the proportion of studies that included HI, the methods used, and the incremental cost-effectiveness ratios (ICERs) reported. When possible, we evaluated how ICERs would change with and without HI. Results Among the 243 immunization CEAs meeting inclusion criteria, 44 studies (18%) included HI. Of those studies, 11 (25%) used dynamic transmission models, whereas the remainder used static models. Sixteen studies allowed for ICER calculations with and without HI ( n = 48 ratios). The inclusion of HI always resulted in more favorable ratios. In 20 cases (42%), adding HI decreased the ICERs enough to cross at least one or more common cost-effectiveness benchmarks for LMICs. Among pneumococcal vaccination studies, including HI in the analyses decreased seven of 24 ICERs enough to cross at least one cost-effectiveness benchmark. Conclusion The full value of immunization may be underestimated without considering a scenario in which HI is achieved. Given the evidence in pneumococcal CEAs, COVID-19 vaccine value assessments should aim to show ICERs with and without HI to inform decision-making in LMICs. Supplementary Information The online version contains supplementary material available at 10.1007/s40258-021-00711-y.

show abstract

Cost-effectiveness analysis of routine 13-valent pneumococcal conjugate vaccinations in Chinese infants

Abstract: The PCV-13 vaccination is likely to be cost-effective at the current Chinese prices and ceiling threshold ($8,382).

Cited by 14 publications

References 36 publications

Pneumococcal Vaccination for Children in Asian Countries: A Systematic Review of Economic Evaluation Studies

Pneumococcal Vaccination for Children in Asian Countries: A Systematic Review of Economic Evaluation Studies

Broad protective immune responses elicited by bacterium-like particle-based intranasal pneumococcal particle vaccine displaying PspA2 and PspA4 fragments

Herd Immunity Effects in Cost-Effectiveness Analyses among Low- and Middle-Income Countries

Contact Info

Product

Resources

About